Mountain Valley MD Provides Year-End Business Update, Advances Commercialization Across Core Platforms

Executive Summary

• Mountain Valley MD provided a comprehensive year‑end update highlighting significant commercial and field‑validation progress across its three core technologies: Quicksome™ nutraceutical delivery, Agrarius™ agricultural signaling, and Soluvec™ 1% ivermectin formulation.
• Agrarius™ trials in Brazil showed yield increases of up to 50 % in younger citrus orchards and strong gains across corn, sugarcane, soybeans, cotton, and potatoes, supporting expansion plans for 2026.
• Quicksome™ licensing with Circadian Wellness continued strong sales of “Eons Dialed” and “Eons Deeper Sleep,” and the company expects a new fenugreek testosterone product launch in H1 2026.

Key Details

• Nutraceuticals – Quicksome™
• Ongoing exclusive manufacturing/licensing with U.S. GMP partner supporting Circadian Wellness’s sublingual products “Eons Dialed” and “Eons Deeper Sleep,” which reported positive consumer reception and sales throughout 2025.
• Business development pipeline includes formulations for peri‑menopausal hot flashes, post‑workout recovery, anti‑inflammation, joint health, and a fenugreek glycosides testosterone tablet (expected launch H1 2026).

• “Mountains Of…” brand holds U.S. trademarks in Sleep, Energy, Relief, Libido, and Lean; distribution partners may market under MVMD or white‑label brands.

• Agriculture – Agrarius™

• Exclusive North‑America‑to‑Caribbean license with Agrarius Corp.; product applied via sprayer as a plant‑signaling additive.
• Brazil citrus trials (Hamlin, Valencia, Pera) demonstrated:
  • Hamlin: ~15 % productivity increase per hectare; 22 % total yield boost; reduced HLB symptom boxes by 20.
  • Valencia: 49 % average yield increase.
  • Younger orchards (including Pera): >50 % productivity gains, stronger vigor, improved flowering/fruit set, enhanced drought resilience.
• Additional crop results in Brazil & Colombia:
  • Corn: +14.8 % and +11.2 % yields in UNESP trials.
  • Sugarcane: +8‑12 t/ha yield; higher sugar content; reduced pest damage.
  • Soybeans: +6.34 sacs/ha average (some >15 %).
  • Cotton, Potatoes: Yield gains of 18.5 % (potatoes) and increased bolls per plant (cotton).
• Drought stress tests showed markedly lower yield losses for Agrarius‑treated crops.

• Ongoing large‑scale pasture grass program in Colombia with FEDEGAN & National University of Colombia; final results expected Q1 2026.

• Husbandry Animals / Aquatic Species – Soluvec™ 1%

• Quicksol™‑based ivermectin formulation (Soluvec™ 1%) achieved nine‑month stability at room and refrigerated temperatures.
• Exclusive license in Bangladesh produced ~200 t of Soluvec™‑coated fish feed; royalty revenues below expectations due to market disruption (Cyclone Remal, 2024).

• Strategic review underway to potentially modify territorial exclusivity in Bangladesh and explore new licensing partners in Latin America; focus on low‑capital, royalty‑based arrangements.

• Forward‑Looking Statements

• Anticipated launch of fenugreek testosterone product H1 2026.
• Expected commercial expansion of Agrarius™ in Brazil during 2026.
• Ongoing discussions for additional Soluvec™ licensing partners in Latin America.

Notable Quotes

• “Throughout 2025, we have remained focused on disciplined execution across each of our business lines… the progress we have made … positions the Company for the next phase of measured growth.” – Dennis Hancock, President & CEO
• “The Brazil citrus trial demonstrates that Agrarius™ delivered substantial yield improvements, stronger plant health, and meaningful mitigation of Greening stress in citrus.” – Dennis Hancock
• “Soluvec™ remains an important asset for the Company, and we are working to align it with partners who can advance this opportunity effectively as we move into 2026.” – Dennis Hancock